The Motley Fool

These 2 FTSE 100 stocks could give you a comfortable retirement

Image source: Getty Images.

There are not many companies that can claim Brexit is already helping them win business. BAE Systems (LSE: BA) might not be stating this publicly, but over the past few months, the company has emerged as a front-runner for the success story of Brexit Britain.

At the end of June, it was revealed that BAE had beaten Italian and Spanish rivals to win a £20bn contract to build Australia‘s new fleet of warships over 30 years. The company is also likely to be instrumental in helping the UK government develop a new next-generation fighter jet — a commitment by policymakers to ensure Britain retains its cutting-edge combat expertise after Brexit.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Details on the air combat strategy are expected to released this week at the Farnborough Airshow.

Ships and planes are only part of BAE’s arsenal. The company is also a world leader in cybersecurity, a market that is seeing rapid growth around the world.

In other words, BAE is well positioned for growth over the next few decades. And I believe the company’s potential makes it the perfect pick for any retirement portfolio.

Long-term focus 

Unlike most companies, BAE tends to sign multi-decade development and maintenance contracts with its customers. Primarily because competitors cannot access its intellectual property. Warren Buffett always mentions a company’s ‘moat’ when talking about its investment potential, and thanks to its intellectual property, BAE’s ‘moat’ is both wide and deep.

With this being the case, I believe the stock’s current valuation of 14.8 times forward earnings is not that demanding, especially when analysts think EPS could jump 31% over the next two years.

Not only is the company on a growth trajectory, but the stock also supports a dividend yield of 3.4% with the distribution covered twice by EPS.

If you are looking for an income-growth stock to include in your retirement portfolio, BAE looks to me to be the perfect buy.

Return to growth 

Another company that I believe is well placed to churn out steady returns for investors over the long term is AstraZeneca (LSE: AZN).

With the company expected to return to growth in 2018, after five years of stagnation, investors have recently pushed shares in Astra to a new all-time high. This vote of confidence in a business is also a vote of confidence in management’s strategy to pursue the development of oncology treatments.

City analysts believe the launch of new treatments will help the company boost EPS by 53% in 2018 and then 16% in 2019 (to $3.87). Unfortunately, even after this growth, Astra’s earnings will still be below the high-water mark of $4.94 reached in 2012, but the return to growth is more symbolic for the group, which has been struggling to ignite revenue expansion since 2012 after it started to lose exclusivity over its flagship Crestor product.

A return to growth proves to investors and analysts that Astra is on the comeback trail. City analysts believe that some of the company’s cancer treatments currently under development could easily replace the lost sales from Crestor over the next few years. 

Considering these forecasts, even though the stock has recently hit a new all-time high, I believe there could be further gains on the horizon especially as the stock’s current valuation of 18.8 times 2019 earnings is below the sector average of 20.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.